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resolution of signs/symptoms, and survival. Financial
data were collected for the time of hospitalization.
RESULTS: Eleven patients have been enrolled. The
average age of the patients is 57 years (range 40–80). The
majority (64%) of the patients were female and 55% of
the patients had lymphoma. The infection was microbio-
logically documented in 27%, clinically documented in
46%, and twenty-seven percent of patients had a fever 
of unknown origin. The average length of hospitaliza-
tion was 9 days (range 3–27). One patient had an adverse
event due to an anti-infective and included chills and
rigors with amphotericin-B lipid complex. The average
number of febrile days was 3 (range 1–8). Every patient
except one had resolution of signs and symptoms of 
the infection. One patient died due to a viral pneumonia.
The anti-infective utilized most frequently was imipenem/
cilastatin. The average cost of hospitalization per patient
was $22,438 (range $5,222.60–$53,398.95). The average
cost of pharmaceuticals per patient was $6,947.50 (range
$2,929.81–$18,642.82).
CONCLUSIONS: Infectious complications in cancer
patients can produce morbidity and mortality as well 
as be costly. Infectious disease outcomes can easily be 
collected utilizing a Palm handheld.
CANCER—Economic Outcomes Presentations
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OBJECTIVES: Gemcitabine/Cisplatin (Gem/Cis) is a
standard regime commonly used in the treatment of 
non-small cell lung cancer. This study uses currently 
available clinical trial data to evaluate the cost implica-
tions of Gem/Cis versus other combination regimes in
Germany.
METHODS: Two published randomised controlled clin-
ical trials were used for this retrospective cost analysis to
evaluate and compare the cost of platinum-based combi-
nation regimes. Comella et al. (2000) compared, among
others, Gem/Cis versus Vinorelbine/Cisplatin (Vin/Cis)
and Schiller et al. (2000) compares Gem/Cis with 
Paclitaxel/Cisplatin (Pac/Cis), Paclitaxel/Carboplatin
(Pac/Carbo) and Docetaxel/Cisplatin (Doc/Cis). Equal
efﬁcacy was assumed for the analysis. Resource use and
unit costs associated with both treatment and toxicity
management were collected from the perspective of a
German sickness fund. Only direct cost (acquisition 
and administration of chemotherapy, hospitalisation and
other medical resource use) were considered.
RESULTS: Based on the Comella et al. (2000) clinical
trial, Gem/Cis was associated with lower overall costs
compared to Vin/Cis (€7638 vs. €8143). The higher
acquisition cost of Gem/Cis was more than compensated
by lower drug administration cost (€798 vs. €1278) and
fewer adverse events resulting in fewer hospitalisations
(€1633 vs. €2680). Based on the Schiller et al. (2000),
Gem/Cis was associated with the lowest overall costs 
of all ﬁrst-line treatment arms, Pac/Carbo and Pac/Cis
(€8.418 vs. €12.268 and €11.050). Even though the drug
acquisition cost of Gem/Cis was lower than Doc/Cis,
higher administration cost lead to slightly higher total
cost of Gem/Cis compared to Doc/Cis (€8418 vs. €8331).
CONCLUSIONS: From the perspective of German 
sickness funds, Gem/Cis as ﬁrst line treatment offers cost
advantages over Pac/Cis and Pac/Carbo in the treatment
of non-small cell lung cancer. Further research is 
necessary to validate these ﬁndings in a setting outside of
clinical trials.
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OBJECTIVES: Data on costs of care and typical care
paths for patients with malignant lymphomas in Germany
are scarce. The aims of this prospective health economic
survey are to identify typical clinical pathways and assess
the costs and clinical beneﬁts of different treatment 
settings and modalities for patients with newly diagnosed
malignant lymphomas.
METHODS: The recruitment of patients for this project
started in 2000 and will be continued through 2003 in
the Cologne and Saarland regions, Germany. Data on
resource consumption and outcomes are collected
prospectively by means of a patient book and a health
economic questionnaire. For the cohort of the one-year
pilot phase, hospital costs and costs of chemotherapy 
for the ﬁrst 6 months since initial diagnosis were 
calculated.
RESULTS: 192 patients have been recruited during 
the pilot phase. Of these, 22 (11,5%) were diagnosed
with Hodgkin’s disease (HD), 111 (57,8%) with non-
Hodgkin’s lymphoma (NHL), 36 (18,8%) with chronic
lymphatic leukemia (CLL) and 18 (9,4%) with multiple
myeloma (MM) (5 = 2,6% undeﬁned). The treatment
setting was as follows: 72 (43,6%) of the patients were
treated in an outpatient setting, 37 (22,4%) in an 
inpatient setting and 56 (33,9%) in a combined inpatient 
and outpatient setting. 54 (33,5%) patients were treated
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within and 74 (46,0%) outside of clinical trials (33 =
20,5% undeﬁned). For HD patients, mean hospital costs
and mean costs of chemotherapy during the ﬁrst 6 months
after initial diagnosis were €6.336,95 and €10.039,73
respectively, for NHL patients €9.787,15 and €6.720,93,
for CLL €1.055,31 and €749,04 respectively, and for
MM patients €9.016,12 and €4.870,57.
CONCLUSIONS: The continuation of this project will
make it possible to determine cost-of-illness and cost-
effectiveness ratios of different treatment modalities for
patients with malignant lymphomas and to develop
guidelines for clinical pathways.
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OBJECTIVE: To quantify the economic effect on 
employers when the spouse or dependent of an employee
is diagnosed with cancer.
METHODS: Costs based on claims data for ﬁve major
employers (number of employees exceeds 100,000) over
the period of 1995–1998 were analyzed from the employ-
ers’ perspectives. The employers’ burden is measured in
terms of direct health-related costs and indirect produc-
tivity costs (i.e., both lost worktime and reduced at-work
performance). Costs for employees who had a family
member with cancer were compared to costs for employ-
ees who did not. For employees who had a family member
with cancer, the relationship between the employee’s costs
and the timing of the family member’s cancer diagnosis
and treatment was examined. Regression analyses were
used to estimate the incremental costs associated with
caring for a family member before, during and after the
diagnosis of cancer.
RESULTS: Caregiving costs were most pronounced
during the 3-month period leading up to and the 3-month
period following diagnosis. Loss of productivity ac-
counted for most of the incremental costs and reached
approximately $1,500 per employee per year. Medical
and drug costs added approximately $230 per employee
per year. When a family member suffered from anemia in
addition to cancer, the costs during the anemia period
(deﬁned as four weeks preceding through four weeks 
following a claims diagnosis of anemia) were over 40
percent higher than in comparable cancer periods without
anemia.
CONCLUSIONS: The economic impact of caregiving for
a family member with cancer is signiﬁcant, and translates
into increased workplace costs. Moreover, this cost in-
crease is more pronounced when cancer-related anemia is
present. These patterns suggest that programs to prevent
or quickly treat a family member’s cancer and any related
anemia could yield indirect beneﬁts to employers by
reducing the burden on employees as caregivers.
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Colorectal cancer is the third most common form of
cancer, representing an estimated 135,400 cases and
56,700 deaths in 2001. Because early detection of col-
orectal cancer can signiﬁcantly reduce 1-year and 5-year
relative survival rates, screening strategies are highly 
recommended. More research into the cost-effectiveness
of new screening technique compared to current methods
is needed.
OBJECTIVES: This analysis attempts to compare the
cost-effectiveness of conventional colonoscopy and
virtual colonoscopy (CT scan) as screening strategies for
the prevention of colorectal cancers in the general 
population.
METHODS: A literature review was conducted to obtain
all relevant costs and probabilities. A spreadsheet model
was constructed to perform the analysis using a hypo-
thetical cohort of the general population over age 50
years from the societal perspective using 2001 US dollars.
A series of one-way sensitivity analysis were performed
on all costs and probabilities obtained from published 
literature.
RESULTS: In the base-case analysis, the number of 
life-years saved per 100,000 was 4000 and 5600 for
virtual and conventional colonoscopy respectively. The
average cost per life-year saved was estimated at $48,200
for virtual colonoscopy and $52,200 for conventional
colonoscopy compared to no screening. The incremental
cost-effectiveness ratio (ICER) of conventional col-
onoscopy versus virtual colonoscopy was $62,100. The
model was most sensitive to the ranges used for the 
discount rate, sensitivity of conventional colonoscopy,
and the cost of conventional colonoscopy.
CONCLUSION: The ICER of conventional to virtual
colonoscopy is borderline unfavorable. Nevertheless,
because of the greater number of life-years saved with
conventional colonoscopy, it appears more favorable than
virtual colonoscopy. Due to the closeness in CEA results,
and the substantial changes with different parameter
assumptions, e.g. combinations of screening strategies
and differences in compliance rates, further data and
analyses are needed to derive a robust conclusion.
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